AstraZeneca CEO Pascal Soriot saw his pay fall last year along with the company's fortunes, but that didn't keep large blocks of shareholders from displaying their distaste for the company's compensation outlay for him and board members. Just short of 40% voted against the U.K. drugmaker's pay program. A spokesperson told The Guardian that the company had not gotten much indication in advance of the vote that shareholders might be miffed over compensation, but that "it is our priority to carefully analyze it and talk to our shareholders to fully understand any concerns."